MISSION

This Group aims to challenge, re-define and develop standards of care for loco-regional as well as systemic treatments for lung cancer. This extends to mesothelioma and thymomas. Projects are designed to integrate disciplines such as imaging, translational research, quality of life and quality assurance. The Group is also focused on studying the use of immunotherapy to treat lung cancer.

PRACTICE CHANGING RESEARCH

  • Lung cancer Group

    EORTC 08983 – Phase III study of Tomudex and Cisplatin versus Cisplatin in Malignant Pleural Mesothelioma.

    EORTC found that combination treatment of cisplatin plus raltitrexed improved overall survival without affecting health-related quality of life in patients with Malignant Pleural Mesothelioma (cancer of the lining of the lungs, known as the pleura).

    READ MORE

  • Lung cancer Group

    EORTC 22993/08993 – Prophylactic cranial irradiation in extensive disease small cell lung cancer.

    A joint study with the EORTC Radiotherapy and Lung Cancer Groups

    EORTC’s study on prophylactic cranial irradiation (PCI) has been internationally adopted as the standard of treatment in patients with small cell lung cancer. It found that prophylactic cranial irradiation (PCI) reduces the risk of symptomatic brain metastases and improved survival in patients with advanced-disease in small cell lung cancer, without significant difference in cognitive and emotional functioning.

    READ MORE

  • Mar-06
  • Aug-07

LATEST PUBLICATIONS

Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up